{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T21:06:46Z","timestamp":1763500006055,"version":"3.33.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["(26-A-4, 29-A-3, 2020-J-3, 2023-J-03)"],"award-info":[{"award-number":["(26-A-4, 29-A-3, 2020-J-3, 2023-J-03)"]}]},{"name":"Accelerating Regulatory Science Initiative from the Ministry of Health, Labour and Welfare"},{"name":"Grant-in-Aid for Clinical Cancer Research from the Ministry of Health, Labour and Welfare of Japan","award":["(H26-kakushin-teki-gan-ippan-074)"],"award-info":[{"award-number":["(H26-kakushin-teki-gan-ippan-074)"]}]},{"name":"Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development, AMED","award":["JP16ck0106077 and JP19ck0106348."],"award-info":[{"award-number":["JP16ck0106077 and JP19ck0106348."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04752-1","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T06:40:10Z","timestamp":1737700810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1)"],"prefix":"10.1007","volume":"95","author":[{"given":"Masaki","family":"Ri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arisa","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tsujimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiju","family":"Negoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukamoto","family":"Norifumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Tabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishikazu","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Maruta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Yoshimitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kanato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"4752_CR1","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.3390\/cancers12123576","volume":"12","author":"MA Legarda","year":"2020","unstructured":"Legarda MA, Cejalvo MJ, de la Rubia J (2020) Recent advances in the treatment of patients with multiple myeloma. Cancers 12:3576","journal-title":"Cancers"},{"key":"4752_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CMAR.S105163","volume":"9","author":"M Mohan","year":"2017","unstructured":"Mohan M, Matin A, Davies FE (2017) Update on the optimal use of bortezomib in the treatment of multiple myeloma. Cancer Manag Res 9:51\u201363","journal-title":"Cancer Manag Res"},{"key":"4752_CR3","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","volume":"28","author":"MV Mateos","year":"2010","unstructured":"Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF (2010) Bortezomib plus Melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 28:2259\u20132266","journal-title":"J Clin Oncol"},{"key":"4752_CR4","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","volume":"370","author":"T Facon","year":"2007","unstructured":"Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial. Lancet 370:1209\u20131218","journal-title":"Lancet"},{"key":"4752_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J (2020) Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 395:132\u2013141","journal-title":"Lancet"},{"key":"4752_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J (2018) Daratumumab plus Bortezomib, Melphalan, and Prednisone for untreated myeloma. N Engl J Med 378:518\u2013528","journal-title":"N Engl J Med"},{"key":"4752_CR7","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1111\/cas.15484","volume":"113","author":"D Maruyama","year":"2022","unstructured":"Maruyama D, Iida S, Machida R, Kusumoto S, Fukuhara N, Yamauchi N, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Usuki K, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Ota S, Ohtsuka E, Hanamura I, Suzuki Y, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Fukuhara S, Tsukasaki K, Nagai H (2022) Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105). Cancer Sci 113:3267\u20133270","journal-title":"Cancer Sci"},{"key":"4752_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/bjh.16878","volume":"192","author":"D Maruyama","year":"2021","unstructured":"Maruyama D, Iida S, Ogawa G, Fukuhara N, Seo S, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Hangaishi A, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Minauchi K, Ohtsuka E, Hanamura I, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Tsukasaki K, Nagai H (2021) Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105). Br J Haematol 192:531\u2013541","journal-title":"Br J Haematol"},{"key":"4752_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.yjmcc.2013.02.008","volume":"59","author":"K Maekawa","year":"2013","unstructured":"Maekawa K, Hirayama A, Iwata Y, Tajima Y, Nishimaki-Mogami T, Sugawara S, Ueno N, Abe H, Ishikawa M, Murayama M, Matsuzawa Y, Nakanishi H, Ikeda K, Arita M, Taguchi R, Minamino N, Wakabayashi S, Soga T, Saito Y (2013) Global metabolomic analysis of heart tissue in a hamster model for dilated cardiomyopathy. J Mol Cell Cardiol 59:76\u201385","journal-title":"J Mol Cell Cardiol"},{"key":"4752_CR10","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1111\/cas.14178","volume":"110","author":"K Maekawa","year":"2019","unstructured":"Maekawa K, Ri M, Nakajima M, Sekine A, Ueda R, Tohkin M, Miyata N, Saito Y, Iida S (2019) Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma. Cancer Sci 110:3267\u20133274","journal-title":"Cancer Sci"},{"key":"4752_CR11","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473","journal-title":"Leukemia"},{"key":"4752_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00280-018-3655-z","volume":"82","author":"K Saito","year":"2018","unstructured":"Saito K, Ikeda M, Kojima Y, Hosoi H, Saito Y, Kondo S (2018) Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand-foot skin reactions in sorafenib-treated patients. Cancer Chemother Pharmacol 82:677\u2013684","journal-title":"Cancer Chemother Pharmacol"},{"key":"4752_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jchromb.2017.04.019","volume":"1055\u20131056","author":"K Saito","year":"2017","unstructured":"Saito K, Ohno Y, Saito Y (2017) Enrichment of resolving power improves ion-peak quantification on a lipidomics platform. J Chromatogr B Analyt Technol Biomed Life Sci 1055\u20131056:20\u201328","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"4752_CR14","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/toxics3030294","volume":"3","author":"C Meregalli","year":"2015","unstructured":"Meregalli C (2015) An overview of Bortezomib-Induced neurotoxicity. Toxics 3:294\u2013303","journal-title":"Toxics"},{"key":"4752_CR15","doi-asserted-by":"publisher","first-page":"104353","DOI":"10.1016\/j.critrevonc.2024.104353","volume":"197","author":"Y Yang","year":"2024","unstructured":"Yang Y, Zhao B, Lan H, Sun J, Wei G (2024) Bortezomib-induced peripheral neuropathy: clinical features, molecular basis, and therapeutic approach. Crit Rev Oncol\/Hematol 197:104353","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"4752_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","volume":"86","author":"MA Dimopoulos","year":"2011","unstructured":"Dimopoulos MA, Mateos M-V, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine D-L, Liu K, Deraedt W, Cakana A, Van De Velde H, San Miguel JF (2011) Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib\u2013melphalan\u2013prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 86:23\u201331","journal-title":"Eur J Haematol"},{"key":"4752_CR17","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.3324\/haematol.2012.067793","volume":"97","author":"B Arnulf","year":"2012","unstructured":"Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W, Moreau P (2012) Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 97:1925\u20131928","journal-title":"Haematologica"},{"key":"4752_CR18","first-page":"3935","volume":"10","author":"R Zhao","year":"2020","unstructured":"Zhao R, Xie Y, Yang B, Wang C, Huang Q, Han Y, Yang L, Yan S, Wang X, Fu C, Wu D, Wu X (2020) Identification of metabolic biomarkers to predict treatment outcome and disease progression in multiple myeloma. Am J Cancer Res 10:3935\u20133946","journal-title":"Am J Cancer Res"},{"key":"4752_CR19","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.leukres.2015.02.011","volume":"39","author":"Y Nagata","year":"2015","unstructured":"Nagata Y, Ishizaki I, Waki M, Ide Y, Hossen MA, Ohnishi K, Miyayama T, Setou M (2015) Palmitic acid, verified by lipid profiling using secondary ion mass spectrometry, demonstrates anti-multiple myeloma activity. Leuk Res 39:638\u2013645","journal-title":"Leuk Res"},{"key":"4752_CR20","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-12-2917","volume":"19","author":"L Puchades-Carrasco","year":"2013","unstructured":"Puchades-Carrasco L, Lecumberri R, Mart\u00ednez-L\u00f3pez J, Lahuerta JJ, Mateos MV, Pr\u00f3sper F, San-Miguel JF, Pineda-Lucena A (2013) Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission. Clin Cancer Res 19:4770\u20134779","journal-title":"Clin Cancer Res"},{"key":"4752_CR21","doi-asserted-by":"publisher","first-page":"e0169263","DOI":"10.1371\/journal.pone.0169263","volume":"12","author":"D Zittema","year":"2017","unstructured":"Zittema D, Casteleijn NF, Bakker SJ, Boesten LS, Duit AA, Franssen CF, Gaillard CA, Gansevoort RT (2017) Urine concentrating capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy patients with renal impairment. PLoS ONE 12:e0169263","journal-title":"PLoS ONE"},{"key":"4752_CR22","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s11255-015-0986-0","volume":"47","author":"A Al-Ani","year":"2015","unstructured":"Al-Ani A, Al-Jalham K, Ibrahim T, Majzoub A, Al-Rayashi M, Hayati A, Mubarak W, Al-Rayahi J, Khairy AT (2015) Factors determining renal impairment in unilateral ureteral colic secondary to calcular disease: a prospective study. Int Urol Nephrol 47:1085\u20131090","journal-title":"Int Urol Nephrol"},{"key":"4752_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00774-006-0705-0","volume":"24","author":"T Ogawa","year":"2006","unstructured":"Ogawa T, Ishida-Kitagawa N, Tanaka A, Matsumoto T, Hirouchi T, Akimaru M, Tanihara M, Yogo K, Takeya T (2006) A novel role of L-serine (L-Ser) for the expression of nuclear factor of activated T cells (NFAT)2 in receptor activator of nuclear factor kappa B ligand (RANKL)-induced osteoclastogenesis in vitro. J Bone Min Metab 24:373\u2013379","journal-title":"J Bone Min Metab"},{"key":"4752_CR24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3892\/ol.2020.11940","volume":"20","author":"Q Shao","year":"2020","unstructured":"Shao Q, Deng L, Liu H, Liu Z, Chen J, Jiang F, Yan S, Fu R (2020) Involvement of MM cell-derived exosomes in T lymphocytes immune responses. Oncol Lett 20:31","journal-title":"Oncol Lett"},{"key":"4752_CR25","doi-asserted-by":"crossref","unstructured":"Khan SA, Ilies MA (2023) The phospholipase A2 superfamily: structure, isozymes, catalysis, physiologic and pathologic roles. Int J Mol Sci 24","DOI":"10.3390\/ijms24021353"},{"key":"4752_CR26","doi-asserted-by":"crossref","unstructured":"Glaser KB (1995) Regulation of Phospholipase A2 Enzymes: Selective Inhibitors and their Pharmacological Potential. In: August JT, Anders MW, Murad F, Coyle J (eds) Advances in Pharmacology Academic Press, pp 31\u201366","DOI":"10.1016\/S1054-3589(08)61011-X"},{"key":"4752_CR27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s12017-009-8092-z","volume":"12","author":"GY Sun","year":"2010","unstructured":"Sun GY, Shelat PB, Jensen MB, He Y, Sun AY, Simonyi A (2010) Phospholipases A2 and inflammatory responses in the central nervous system. Neuromolecular Med 12:133\u2013148","journal-title":"Neuromolecular Med"},{"key":"4752_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1046\/j.1365-2249.1999.00871.x","volume":"116","author":"YH Huang","year":"1999","unstructured":"Huang YH, Sch\u00e4fer-Elinder L, Wu R, Claesson HE, Frosteg\u00e5rd J (1999) Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin Exp Immunol 116:326\u2013331","journal-title":"Clin Exp Immunol"},{"key":"4752_CR29","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1161\/01.ATV.17.5.963","volume":"17","author":"J Frosteg\u00e5rd","year":"1997","unstructured":"Frosteg\u00e5rd J, Huang YH, R\u00f6nnelid J, Sch\u00e4fer-Elinder L (1997) Platelet-activating factor and oxidized LDL induce Immune activation by a common mechanism. Arterioscler Thromb Vasc Biol 17:963\u2013968","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4752_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neulet.2007.07.020","volume":"424","author":"XH Li","year":"2007","unstructured":"Li XH, Long DX, Li W, Wu YJ (2007) Different mechanisms of lysophosphatidylcholine-induced ca(2+) mobilization in N2a mouse and SH-SY5Y human neuroblastoma cells. Neurosci Lett 424:22\u201326","journal-title":"Neurosci Lett"},{"issue":"Pt 2","key":"4752_CR31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1042\/bj3360491","volume":"336","author":"F Okajima","year":"1998","unstructured":"Okajima F, Sato K, Tomura H, Kuwabara A, Nochi H, Tamoto K, Kondo Y, Tokumitsu Y, Ui M (1998) Stimulatory and inhibitory actions of lysophosphatidylcholine, depending on its fatty acid residue, on the phospholipase C\/Ca2\u2009+\u2009system in HL-60 leukaemia cells. Biochem J 336(Pt 2):491\u2013500","journal-title":"Biochem J"},{"key":"4752_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.pbb.2013.03.002","volume":"106","author":"HY Wang","year":"2013","unstructured":"Wang HY, Tsai YJ, Chen SH, Lin CT, Lue JH (2013) Lysophosphatidylcholine causes neuropathic pain via the increase of neuronal nitric oxide synthase in the dorsal root ganglion and cuneate nucleus. Pharmacol Biochem Behav 106:47\u201356","journal-title":"Pharmacol Biochem Behav"},{"key":"4752_CR33","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/exd.14506","volume":"31","author":"AL Severing","year":"2022","unstructured":"Severing AL, Rembe JD, F\u00fcllerer M, St\u00fcrmer EK (2022) Impact of the chronic wound microenvironment and marine omega-3 fatty acids on skin cell regeneration processes. Exp Dermatol 31:725\u2013735","journal-title":"Exp Dermatol"},{"key":"4752_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12944-021-01552-3","volume":"20","author":"M Blaess","year":"2021","unstructured":"Blaess M, Kaiser L, Sommerfeld O, Csuk R, Deigner H-P (2021) Drug triggered pruritus, rash, papules, and blisters\u2013 is AGEP a clash of an altered sphingolipid-metabolism and lysosomotropism of drugs accumulating in the skin? Lipids Health Dis 20:156","journal-title":"Lipids Health Dis"},{"key":"4752_CR35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1177\/1099800415621617","volume":"18","author":"EL Arantes","year":"2016","unstructured":"Arantes EL, Dragano N, Ramalho A, Vitorino D, de-Souza GF, Lima MH, Velloso LA, Ara\u00fajo EP (2016) Topical docosahexaenoic acid (DHA) accelerates skin Wound Healing in rats and activates GPR120. Biol Res Nurs 18:411\u2013419","journal-title":"Biol Res Nurs"},{"key":"4752_CR36","first-page":"56","volume":"64","author":"M Kim","year":"1994","unstructured":"Kim M, Otsuka M, Yu R, Kurata T, Arakawa N (1994) The distribution of ascorbic acid and dehydroascorbic acid during tissue regeneration in wounded dorsal skin of guinea pigs. Int J Vitam Nutr Res 64:56\u201359","journal-title":"Int J Vitam Nutr Res"},{"key":"4752_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/jjco\/hyac198","volume":"53","author":"T Suzuki","year":"2022","unstructured":"Suzuki T, Terada M, Machida R, Kataoka T, Ito Y, Kataoka K, Maruyama D, Nagai H, Group LSGotJCO (2022) Randomized phase III study of daratumumab versus bortezomib plus daratumumab as maintenance therapy after D-MPB for transplant-ineligible patients with untreated multiple myeloma (JCOG1911, B-DASH study). Jpn J Clin Oncol 53:349\u2013354","journal-title":"Jpn J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04752-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04752-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04752-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T06:40:21Z","timestamp":1737700821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04752-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4752"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04752-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"21 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"S.I., J. K., N. T., H. N., K. M., and M. R. report honoraria from Janssen Pharmaceutical. S.I., J. K., H. N., and M. R. report research funding from Janssen Pharmaceutical. The other authors report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"29"}}